Literature DB >> 16113694

Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.

Chihiro Hosoda1, Akito Tanoue, Mari Shibano, Yoshio Tanaka, Masami Hiroyama, Taka-aki Koshimizu, Susanna Cotecchia, Tadaichi Kitamura, Gozoh Tsujimoto, Katsuo Koike.   

Abstract

We examined the contribution of each alpha(1)-adrenoceptor (AR) subtype in noradrenaline (NAd)-evoked contraction in the thoracic aortas and mesenteric arteries of mice. Compared with the concentration-response curves (CRCs) for NAd in the thoracic aortas of wild-type (WT) mice, the CRCs of mutant mice showed a significantly lower sensitivity. The pD(2) value in rank order is as follows: WT mice (8.21) > alpha(1B)-adrenoceptor knockout (alpha(1B)-KO) (7.77) > alpha(1D)-AR knockout (alpha(1D)-KO) (6.44) > alpha(1B)- and alpha(1D)-AR double knockout (alpha(1BD)-KO) (5.15). In the mesenteric artery, CRCs for NAd did not differ significantly between either WT (6.52) and alpha(1B)-KO mice (7.12) or alpha(1D)-KO (6.19) and alpha(1BD)-KO (6.29) mice. However, the CRC maximum responses to NAd in alpha(1D)- and alpha(1BD)-KO mice were significantly lower than those in WT and alpha(1B)-KO mice. Except in the thoracic aortas of alpha(1BD)-KO mice, the competitive antagonist prazosin inhibited the contraction response to NAd with high affinity. However, prazosin produced shallow Schild slopes in the vessels of mice lacking the alpha(1D)-AR gene. In the thoracic aorta, pA(2) values in WT mice for KMD-3213 and BMY7378 were 8.25 and 8.46, respectively, and in alpha(1B)-KO mice they were 8.49 and 9.13, respectively. In the mesenteric artery, pA(2) values in WT mice for KMD-3213 and BMY7378 were 8.34 and 7.47, respectively, and in alpha(1B)-KO mice they were 8.11 and 7.82, respectively. These pharmacological findings were in fairly good agreement with findings from comparison of CRCs, with the exception of the mesenteric arteries of WT and alpha(1B)-KO mice, which showed low affinities to BMY7378. We performed a quantitative analysis of the mRNA expression of each alpha(1)-AR subtype in these vessels in order to examine the correlation between mRNA expression level and the predominance of each alpha(1)-AR subtype in mediating vascular contraction. The rank order of each alpha(1)-AR subtype in terms of its vasoconstrictor role was in fairly good agreement with the level of expression of mRNA of each subtype, that is, alpha(1D)-AR > alpha(1B)-AR > alpha(1A)-AR in the thoracic aorta and alpha(1D)-AR > alpha(1A)-AR > alpha(1B)-AR in the mesenteric artery. No dramatic compensatory change of alpha(1)-AR subtype in mutant mice was observed in pharmacological or quantitative mRNA expression analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113694      PMCID: PMC1576278          DOI: 10.1038/sj.bjp.0706325

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction.

Authors:  S L Hrometz; S E Edelmann; D F McCune; J R Olges; R W Hadley; D M Perez; M T Piascik
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

3.  Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor.

Authors:  A Cavalli; A L Lattion; E Hummler; M Nenniger; T Pedrazzini; J F Aubert; M C Michel; M Yang; G Lembo; C Vecchione; M Mostardini; A Schmidt; F Beermann; S Cotecchia
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 4.  Recent advances in the molecular pharmacology of the alpha 1-adrenergic receptors.

Authors:  R D Guarino; D M Perez; M T Piascik
Journal:  Cell Signal       Date:  1996-08       Impact factor: 4.315

5.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

6.  The use of quantitative RT-PCR to measure mRNA expression in a rat model of focal ischemia--caspase-3 as a case study.

Authors:  D C Harrison; A D Medhurst; B C Bond; C A Campbell; R P Davis; K L Philpott
Journal:  Brain Res Mol Brain Res       Date:  2000-01-10

7.  Alterations of mRNA levels of alpha 1-adrenoceptor subtypes with maturation and ageing in different rat blood vessels.

Authors:  K M Xu; F Tang; C Han
Journal:  Clin Exp Pharmacol Physiol       Date:  1997-06       Impact factor: 2.557

8.  Alpha(1)-adrenoceptor subtypes mediating contractions of the rat mesenteric artery.

Authors:  M B Hussain; I Marshall
Journal:  Eur J Pharmacol       Date:  2000-04-21       Impact factor: 4.432

9.  Immunocytochemical localization of the alpha-1B adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides.

Authors:  M T Piascik; S L Hrometz; S E Edelmann; R D Guarino; R W Hadley; R D Brown
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

10.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03
View more
  9 in total

1.  Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors.

Authors:  Bei Sun; Ekaterina Kintsurashvili; Deborah Ona; Ivana Ignjacev-Lazich; Irene Gavras; Haralambos Gavras
Journal:  Vascul Pharmacol       Date:  2007-01-23       Impact factor: 5.773

2.  Alpha1-adrenoceptors are required for normal male sexual function.

Authors:  A Sanbe; Y Tanaka; Y Fujiwara; H Tsumura; J Yamauchi; S Cotecchia; K Koike; G Tsujimoto; A Tanoue
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

Review 3.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

4.  Size-dependent heterogeneity of contractile Ca2+ sensitization in rat arterial smooth muscle.

Authors:  Toshio Kitazawa; Kazuyo Kitazawa
Journal:  J Physiol       Date:  2012-08-28       Impact factor: 5.182

5.  Luteolin alleviates vascular dysfunctions in CLP-induced polymicrobial sepsis in mice.

Authors:  Soya Rungsung; Thakur Uttam Singh; Kirthika Perumalraja; Archana Mahobiya; Meemansha Sharma; Madhu Cholenahalli Lingaraju; Subhashree Parida; Monalisa Sahoo; Dinesh Kumar
Journal:  Pharmacol Rep       Date:  2022-08-08       Impact factor: 3.919

6.  The α₁B -adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium.

Authors:  Tobias Böhmer; Caroline Manicam; Andreas Steege; Martin C Michel; Norbert Pfeiffer; Adrian Gericke
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

7.  Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances alpha1D-adrenergic receptor constriction.

Authors:  Heather Irina Cohn; David M Harris; Stephanie Pesant; Michael Pfeiffer; Rui-Hai Zhou; Walter J Koch; Gerald W Dorn; Andrea D Eckhart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-22       Impact factor: 4.733

8.  α1D-Adrenoceptors are responsible for the high sensitivity and the slow time-course of noradrenaline-mediated contraction in conductance arteries.

Authors:  Nicla Flacco; Jaime Parés; Eva Serna; Vanessa Segura; Diana Vicente; Miguel Pérez-Aso; María Antonia Noguera; María Dolores Ivorra; John C McGrath; Pilar D'Ocon
Journal:  Pharmacol Res Perspect       Date:  2013-08-28

Review 9.  The Role of Adrenoceptors in the Retina.

Authors:  Yue Ruan; Tobias Böhmer; Subao Jiang; Adrian Gericke
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.